We are de-risking biomedical innovation, turning biomedical knowledge into social and economic value.
More than three decades later, we remain committed in pursuit of pharmaceutical innovation, providing high quality products and striving to deliver superior business results.
The patient is at the heart of what we do, making decisions regarding biometric innovation is usually a complicated and chaotic procedure as it consists of various product options, various facets to ascertain these on, and multiple evaluations at all levels.
Discover our therapeutic areas, where we continuously invest to innovate and deliver therapeutic solutions for patient’s benefit.
Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more
Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more
Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more
28
Mar 2026
Using cholesterol-lowering medications more intensively to achieve a more aggressive target for low-density lipoprotein cholesterol (LDL-C) reduced the rate of major cardiovascular events by one-third among patients with atherosclerotic cardiovascular disease (ASCVD), according to a study presented at the American College of Cardiology's Annual Scientific Session (ACC.26).
28
Mar 2026
The cholesterol-lowering therapy evolocumab reduced the risk of major adverse cardiac events by nearly one-third among patients who had no known significant atherosclerosis and had diabetes, according to a study presented at the American College of Cardiology's Annual Scientific Session.
28
Mar 2026
Black adults with high blood pressure who received dietitian counseling and home deliveries of groceries aligned with the DASH diet—meaning high in fruits, vegetables, whole grains, low-fat dairy, nuts, seeds, legumes and lean proteins—had an average overall reduction in systolic blood pressure of 7 mm Hg at three months overall and a 5 mm Hg reduction compared with participants who received only basic dietary guidance and a grocery stipend, according to a study presented at the American College of Cardiology's Annual Scientific Session (ACC.26).
28
Mar 2026
The investigational drug tonlamarsen—which is designed to lower blood pressure by reducing the production of angiotensinogen, a protein that turns into the hormone that regulates blood pressure—caused a significant and sustained drop in angiotensinogen but its impact on blood pressure was less clear, according to a study presented at the American College of Cardiology's Annual Scientific Session.